Vinita Gupta

About

Challenges have always motivated Vinita Gupta, global CEO of Lupin Limited (Lupin) and chairperson of Lupin Inc. and its U.S. subsidiary Lupin Pharmaceuticals Inc. When Vinita joined her father D.B. Gupta’s pharma business in 1992, Lupin was a major player in tuberculosis drugs and antibiotics. Gupta tasked Vinita with internationalising the business, and by 2001, Lupin’s exports to advanced markets crossed ₹100 crore. Today, Lupin Limited derives 42% of its revenue from the U.S. market. The company reported consolidated revenues of `27,488 crore in FY26; U.S. sales rose 46% YoY. “In the U.S., we have a long-term growth strategy—shifting from generics to complex generics, biosimilars and specialty products,” says Vinita. The company is investing $250 million to establish a new inhalation manufacturing facility in Coral Springs, Florida.